CA2067364A1 - Lipoproteines oxydees et methodes de preparation de celles-ci - Google Patents

Lipoproteines oxydees et methodes de preparation de celles-ci

Info

Publication number
CA2067364A1
CA2067364A1 CA002067364A CA2067364A CA2067364A1 CA 2067364 A1 CA2067364 A1 CA 2067364A1 CA 002067364 A CA002067364 A CA 002067364A CA 2067364 A CA2067364 A CA 2067364A CA 2067364 A1 CA2067364 A1 CA 2067364A1
Authority
CA
Canada
Prior art keywords
lipoproteins
low density
oxidized
density lipoprotein
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002067364A
Other languages
English (en)
Inventor
Eric T. Fossel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2067364A1 publication Critical patent/CA2067364A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
CA002067364A 1989-10-06 1990-10-04 Lipoproteines oxydees et methodes de preparation de celles-ci Abandoned CA2067364A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41838289A 1989-10-06 1989-10-06
US418,382 1989-10-06

Publications (1)

Publication Number Publication Date
CA2067364A1 true CA2067364A1 (fr) 1991-04-07

Family

ID=23657894

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002067356A Abandoned CA2067356A1 (fr) 1989-10-06 1990-10-04 Methodes de traitement des maladies au moyen de lipoproteines oxydees
CA002067364A Abandoned CA2067364A1 (fr) 1989-10-06 1990-10-04 Lipoproteines oxydees et methodes de preparation de celles-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002067356A Abandoned CA2067356A1 (fr) 1989-10-06 1990-10-04 Methodes de traitement des maladies au moyen de lipoproteines oxydees

Country Status (7)

Country Link
EP (2) EP0494992A4 (fr)
JP (2) JPH05501258A (fr)
AU (2) AU7040091A (fr)
BR (2) BR9007725A (fr)
CA (2) CA2067356A1 (fr)
FI (2) FI921431A0 (fr)
WO (2) WO1991005536A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
WO1994023302A1 (fr) * 1993-04-07 1994-10-13 The Australian National University Dosage immunologique de lipoproteines humaines a faible densite modifiees par oxydation presentes dans le plasma
OA12431A (en) * 2000-10-20 2006-04-19 Beate Kehrel Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
SI1684868T1 (sl) * 2003-04-25 2012-05-31 Hambruger Stiftung Zur Foerderung Von Wissensachaft Und Kultur Zdravljenje hiv infekcij s hipoklorasto kislinskooksidizirano človeško krvno plazmo
WO2006059082A1 (fr) * 2004-11-30 2006-06-08 Trigen Limited Lipides oxydés en tant qu’agents désactivants de médicaments de type acides boroniques
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095338A (en) * 1927-08-20 1937-10-12 Ig Farbenindustrie Ag Process for oxidizing organic substances in the liquid phase and apparatus therefor
US2095388A (en) * 1935-08-03 1937-10-12 Bendix Radio Corp Electrical regulator apparatus
US3655700A (en) * 1970-02-02 1972-04-11 Zoecon Corp Oxygenated unsaturated aliphatic carboxylic acids and esters
US4226713A (en) * 1978-04-24 1980-10-07 Goldberg Jack M Diagnostic agents
JPS5810056A (ja) * 1981-07-10 1983-01-20 株式会社クラレ 血液浄化装置
DD243714A1 (de) * 1985-10-08 1987-03-11 Akad Wissenschaften Ddr Verfahren zur stabilisierung von immobilisierter glukoseoxidase

Also Published As

Publication number Publication date
WO1991005536A3 (fr) 1991-08-08
FI921431A (fi) 1992-04-01
FI921431A0 (fi) 1992-04-01
AU7040091A (en) 1991-04-28
JPH05501258A (ja) 1993-03-11
JPH05500963A (ja) 1993-02-25
EP0494992A1 (fr) 1992-07-22
FI921430A (fi) 1992-04-01
FI921430A0 (fi) 1992-04-01
EP0495014A1 (fr) 1992-07-22
WO1991004744A1 (fr) 1991-04-18
AU7045291A (en) 1991-05-16
WO1991005536A2 (fr) 1991-05-02
EP0494992A4 (en) 1993-03-31
BR9007721A (pt) 1992-08-18
CA2067356A1 (fr) 1991-04-07
BR9007725A (pt) 1992-08-18
EP0495014A4 (en) 1993-07-28

Similar Documents

Publication Publication Date Title
Konings Lipid peroxidation in liposomes
JP6806830B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
US5192264A (en) Methods and apparatus for treating disease states using oxidized lipoproteins
Schafer et al. Comparing β-carotene, vitamin E and nitric oxide as membrane antioxidants
Bocci et al. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70
Sagar et al. Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro
Coceani et al. Further evidence implicating a cytochrome P-450-mediated reaction in the contractile tension of the lamb ductus arteriosus.
Edwards et al. Photochemical and pharmacokinetic properties of selected flavins
Babizhayev Accumulation of lipid peroxidation products in human cataracts
CA2067364A1 (fr) Lipoproteines oxydees et methodes de preparation de celles-ci
US5061484A (en) Perfluorochemical emulsion with stabilized vesicles
Wills et al. The formation of peroxides in tissue lipids and unsaturated fatty acids by irradiation
US5366440A (en) Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents
JPS6137735A (ja) ヘモグロビン含有リポソ−ムおよびその製造方法
US4913907A (en) Porphycene anti-cancer agents and treatment methods
EP1181026B1 (fr) Methode amelioree pour traiter des mammiferes au moyen de sang modifie de mammifere
Candide et al. MODIFICATION OF ε‐AMINO GROUP OF LYSINES, CHOLESTEROL OXIDATION AND OXIDIZED LIPID‐APOPROTEIN CROSS‐LINK FORMATION BY PORPHYRIN‐PHOTOSENSITIZED OXIDATION OF HUMAN LOW DENSITY LIPOPROTEINS
US5217716A (en) Method for treating viral infections using oxidized lipoproteins
Halát et al. Effect of partial ischemia on phospholipids and postischemic lipid peroxidation in rabbit spinal cord
WO2000067743A1 (fr) Phagocyte radicalaire
Wolfson et al. Inhibitory effect of retinoic acid on the respiratory burst of adult and cord blood neutrophils and macrophages: potential implication to bronchopulmonary dysplasia.
JPS63188391A (ja) 細菌破壊に及び／又は免疫調節に有効な物質の製造方法並びにこれを使用する方法
Salzberg et al. Protective effect of cholesterol on Friend leukemic cells against photosensitization by hematoporphyrin derivative
Rakovsky et al. Application of ozone in medicine
AU8305691A (en) Method for treating viral infections using oxidized lipoproteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead